论文部分内容阅读
摘要目的研究在肝癌经动脉化学栓塞(TACE)中提高抗癌药物碘油乳化剂的稳定性和其药代动力学的关系。材料与方法评估多柔比星或伊达比星的稳定性超过7 d。经机构伦理委员会批准后,记录8例不可切除的肝癌病人使用最稳定的乳化剂行TACE术后的药代动力学和临床数据。结果最稳定的乳化剂是将伊达比星和碘油以1∶2的比例混合。将多柔比星和碘油以1∶1比例和1∶2比例混合以及将伊达比星
Abstract Objective To study the relationship between the stability of lipiodol emulsifier and its pharmacokinetics in transcatheter arterial chemoembolization (TACE) of hepatocellular carcinoma. MATERIALS AND METHODS Assessment of doxorubicin or idarubic stability over 7 days. Approved by the Institutional Ethics Committee, 8 patients with unresectable HCC were recorded for pharmacokinetics and clinical data after TACE using the most stable emulsifier. The most stable emulsifier resulted in the mixing of idarubicin and lipiodol in a 1: 2 ratio. Doxorubicin and lipiodol were mixed in a 1: 1 ratio and a 1: 2 ratio and idarubicin was added